Fulgent Genetics, Inc. Common Stock (FLGT) Stock
Key stats
- Market cap
- $718.03M
- Price / Earnings ratio
- -7.9x
- EPS (TTM)
- -$3.09
- Volume
- Loading
- 52-week high
- $31.04
- 52-week low
- $13.46
Source: third-party data provider, as of November 13, 2026
Compare with FLGT
Recent news

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
FLGT

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
FLGT

Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
FLGT

Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics Q2 Earnings Call Highlights
FLGT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 68.29
- MACD 12/26/9
- 0.95
- EMA 9 of MACD
- 0.27
- MACD histogram
- 0.67
- SMA 50
- $21.18
- Price above SMA 50
- EMA 50
- $21.15
- Price above EMA 50
- SMA 200
- $19.15
- Price above SMA 200
- EMA 200
- $21.02
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
FLGT

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
FLGT

Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
FLGT

Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics Q2 Earnings Call Highlights
FLGT

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
FLGT

Fulgent Reports Second Quarter 2026 Financial Results
Fulgent Reports Second Quarter 2026 Financial Results
FLGT

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
FLGT

Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulgent Presents Updated FID-007 Data at ASCO 2026
FLGT

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
FLGT

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
FLGT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Fulgent Genetics, Inc. Common Stock
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ming Hsieh | Chairman & CEO | 1956 |
| Mr. Jian Xie | COO & President | 1966 |
| Mr. Paul Kim CPA | Chief Financial Officer | 1967 |
| Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D. | Chief Scientific Officer & Lab Director | 1967 |
| Ms. Natalie Prescott CIPM, CIPP | General Counsel & Chief Privacy Officer | — |
| Ms. Doreen Ng | Vice President of Operations & Compliance | — |
| Mr. Jakub Sram | Vice President of Business Development & Sales | — |
| Ms. Ellen Tsui | Vice President of Human Resources | — |
| Mr. Brandon Perthuis | Chief Commercial Officer | — |
| Mr. Elias Nyankojo | Chief Information Security Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 68.29
- MACD 12/26/9
- 0.95
- EMA 9 of MACD
- 0.27
- MACD histogram
- 0.67
- SMA 50
- $21.18
- Price above SMA 50
- EMA 50
- $21.15
- Price above EMA 50
- SMA 200
- $19.15
- Price above SMA 200
- EMA 200
- $21.02
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $25.00
- Average
- $25.00
- High
- $25.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +12.0 | -7.6 | +28.4 | +13.4 | -20.5 | +10.0 | +12.4 | -3.2 | +33.2 |



